KARO BIO PRESENTS PHASE III CLINICAL TRIALS DESIGN FOR EPROTIROME
STOCKHOLM, Sweden, August 26, 2010. Karo Bio AB (publ) (Reuters: KARO.ST) today presents its development plan for the phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH).There is currently no sufficient treatment available for a majority of HeFH patients. In several clinical phase II studies, eprotirome has shown to have a very compelling efficacy profile for the lowering of blood lipid levels. The planned clinical phase III program is designed to evaluate eprotirome’s safety profile at